nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP3A4—Methylprednisolone—psoriatic arthritis	0.123	0.216	CbGbCtD
Palonosetron—CYP3A4—Triamcinolone—psoriatic arthritis	0.0934	0.164	CbGbCtD
Palonosetron—CYP3A4—Betamethasone—psoriatic arthritis	0.0802	0.141	CbGbCtD
Palonosetron—CYP3A4—Prednisolone—psoriatic arthritis	0.0791	0.139	CbGbCtD
Palonosetron—CYP3A4—Prednisone—psoriatic arthritis	0.0747	0.131	CbGbCtD
Palonosetron—CYP2D6—Dexamethasone—psoriatic arthritis	0.0733	0.129	CbGbCtD
Palonosetron—CYP3A4—Dexamethasone—psoriatic arthritis	0.0466	0.0817	CbGbCtD
Palonosetron—Arrhythmia—Triamcinolone—psoriatic arthritis	0.00131	0.00305	CcSEcCtD
Palonosetron—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.00131	0.00305	CcSEcCtD
Palonosetron—Hyperglycaemia—Prednisone—psoriatic arthritis	0.00131	0.00305	CcSEcCtD
Palonosetron—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00128	0.00299	CcSEcCtD
Palonosetron—Erythema—Triamcinolone—psoriatic arthritis	0.00128	0.00298	CcSEcCtD
Palonosetron—Erythema—Methylprednisolone—psoriatic arthritis	0.00128	0.00297	CcSEcCtD
Palonosetron—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00128	0.00297	CcSEcCtD
Palonosetron—Dysgeusia—Triamcinolone—psoriatic arthritis	0.00125	0.00292	CcSEcCtD
Palonosetron—Eye disorder—Dexamethasone—psoriatic arthritis	0.00125	0.0029	CcSEcCtD
Palonosetron—Eye disorder—Betamethasone—psoriatic arthritis	0.00125	0.0029	CcSEcCtD
Palonosetron—Angiopathy—Dexamethasone—psoriatic arthritis	0.00121	0.00282	CcSEcCtD
Palonosetron—Angiopathy—Betamethasone—psoriatic arthritis	0.00121	0.00282	CcSEcCtD
Palonosetron—Convulsion—Prednisolone—psoriatic arthritis	0.0012	0.0028	CcSEcCtD
Palonosetron—Hypertension—Prednisolone—psoriatic arthritis	0.0012	0.00279	CcSEcCtD
Palonosetron—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00119	0.00277	CcSEcCtD
Palonosetron—Arrhythmia—Betamethasone—psoriatic arthritis	0.00119	0.00277	CcSEcCtD
Palonosetron—Bradycardia—Prednisone—psoriatic arthritis	0.00118	0.00275	CcSEcCtD
Palonosetron—Alopecia—Betamethasone—psoriatic arthritis	0.00118	0.00274	CcSEcCtD
Palonosetron—Alopecia—Dexamethasone—psoriatic arthritis	0.00118	0.00274	CcSEcCtD
Palonosetron—Discomfort—Prednisolone—psoriatic arthritis	0.00117	0.00272	CcSEcCtD
Palonosetron—Erythema—Dexamethasone—psoriatic arthritis	0.00116	0.0027	CcSEcCtD
Palonosetron—Erythema—Betamethasone—psoriatic arthritis	0.00116	0.0027	CcSEcCtD
Palonosetron—Connective tissue disorder—Prednisone—psoriatic arthritis	0.00114	0.00266	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00113	0.00264	CcSEcCtD
Palonosetron—Shock—Prednisolone—psoriatic arthritis	0.00112	0.0026	CcSEcCtD
Palonosetron—Convulsion—Triamcinolone—psoriatic arthritis	0.00111	0.00258	CcSEcCtD
Palonosetron—Tachycardia—Prednisolone—psoriatic arthritis	0.00111	0.00258	CcSEcCtD
Palonosetron—Convulsion—Methylprednisolone—psoriatic arthritis	0.00111	0.00257	CcSEcCtD
Palonosetron—Hypertension—Triamcinolone—psoriatic arthritis	0.0011	0.00257	CcSEcCtD
Palonosetron—Hypertension—Methylprednisolone—psoriatic arthritis	0.0011	0.00256	CcSEcCtD
Palonosetron—Myalgia—Triamcinolone—psoriatic arthritis	0.00109	0.00253	CcSEcCtD
Palonosetron—Arthralgia—Methylprednisolone—psoriatic arthritis	0.00109	0.00253	CcSEcCtD
Palonosetron—Myalgia—Methylprednisolone—psoriatic arthritis	0.00109	0.00253	CcSEcCtD
Palonosetron—Eye disorder—Prednisone—psoriatic arthritis	0.00108	0.00253	CcSEcCtD
Palonosetron—Anxiety—Methylprednisolone—psoriatic arthritis	0.00108	0.00252	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00108	0.00251	CcSEcCtD
Palonosetron—Discomfort—Triamcinolone—psoriatic arthritis	0.00108	0.0025	CcSEcCtD
Palonosetron—Discomfort—Methylprednisolone—psoriatic arthritis	0.00107	0.0025	CcSEcCtD
Palonosetron—Dry mouth—Triamcinolone—psoriatic arthritis	0.00106	0.00248	CcSEcCtD
Palonosetron—Angiopathy—Prednisone—psoriatic arthritis	0.00105	0.00245	CcSEcCtD
Palonosetron—Immune system disorder—Prednisone—psoriatic arthritis	0.00105	0.00244	CcSEcCtD
Palonosetron—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00104	0.00243	CcSEcCtD
Palonosetron—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00104	0.00242	CcSEcCtD
Palonosetron—Arrhythmia—Prednisone—psoriatic arthritis	0.00104	0.00241	CcSEcCtD
Palonosetron—Infection—Triamcinolone—psoriatic arthritis	0.00104	0.00241	CcSEcCtD
Palonosetron—Infection—Methylprednisolone—psoriatic arthritis	0.00103	0.00241	CcSEcCtD
Palonosetron—Shock—Triamcinolone—psoriatic arthritis	0.00103	0.00239	CcSEcCtD
Palonosetron—Insomnia—Prednisolone—psoriatic arthritis	0.00103	0.00239	CcSEcCtD
Palonosetron—Alopecia—Prednisone—psoriatic arthritis	0.00103	0.00239	CcSEcCtD
Palonosetron—Shock—Methylprednisolone—psoriatic arthritis	0.00102	0.00238	CcSEcCtD
Palonosetron—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.00102	0.00238	CcSEcCtD
Palonosetron—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00102	0.00238	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—psoriatic arthritis	0.00102	0.00237	CcSEcCtD
Palonosetron—Paraesthesia—Prednisolone—psoriatic arthritis	0.00102	0.00237	CcSEcCtD
Palonosetron—Tachycardia—Triamcinolone—psoriatic arthritis	0.00102	0.00237	CcSEcCtD
Palonosetron—Mental disorder—Prednisone—psoriatic arthritis	0.00102	0.00237	CcSEcCtD
Palonosetron—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00102	0.00237	CcSEcCtD
Palonosetron—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00101	0.00235	CcSEcCtD
Palonosetron—Malnutrition—Prednisone—psoriatic arthritis	0.00101	0.00235	CcSEcCtD
Palonosetron—Erythema—Prednisone—psoriatic arthritis	0.00101	0.00235	CcSEcCtD
Palonosetron—Convulsion—Dexamethasone—psoriatic arthritis	0.001	0.00234	CcSEcCtD
Palonosetron—Convulsion—Betamethasone—psoriatic arthritis	0.001	0.00234	CcSEcCtD
Palonosetron—Hypertension—Dexamethasone—psoriatic arthritis	0.001	0.00233	CcSEcCtD
Palonosetron—Hypertension—Betamethasone—psoriatic arthritis	0.001	0.00233	CcSEcCtD
Palonosetron—Myalgia—Dexamethasone—psoriatic arthritis	0.000988	0.0023	CcSEcCtD
Palonosetron—Myalgia—Betamethasone—psoriatic arthritis	0.000988	0.0023	CcSEcCtD
Palonosetron—Anxiety—Dexamethasone—psoriatic arthritis	0.000984	0.00229	CcSEcCtD
Palonosetron—Anxiety—Betamethasone—psoriatic arthritis	0.000984	0.00229	CcSEcCtD
Palonosetron—Discomfort—Betamethasone—psoriatic arthritis	0.000976	0.00227	CcSEcCtD
Palonosetron—Discomfort—Dexamethasone—psoriatic arthritis	0.000976	0.00227	CcSEcCtD
Palonosetron—Hypotension—Methylprednisolone—psoriatic arthritis	0.000973	0.00227	CcSEcCtD
Palonosetron—Pain—Prednisolone—psoriatic arthritis	0.00097	0.00226	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000958	0.00223	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—psoriatic arthritis	0.000951	0.00221	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000951	0.00221	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000948	0.00221	CcSEcCtD
Palonosetron—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000947	0.0022	CcSEcCtD
Palonosetron—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000947	0.0022	CcSEcCtD
Palonosetron—Insomnia—Triamcinolone—psoriatic arthritis	0.000944	0.0022	CcSEcCtD
Palonosetron—Insomnia—Methylprednisolone—psoriatic arthritis	0.000942	0.00219	CcSEcCtD
Palonosetron—Infection—Dexamethasone—psoriatic arthritis	0.00094	0.00219	CcSEcCtD
Palonosetron—Infection—Betamethasone—psoriatic arthritis	0.00094	0.00219	CcSEcCtD
Palonosetron—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000937	0.00218	CcSEcCtD
Palonosetron—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000935	0.00218	CcSEcCtD
Palonosetron—Anaemia—Prednisone—psoriatic arthritis	0.000934	0.00217	CcSEcCtD
Palonosetron—Shock—Dexamethasone—psoriatic arthritis	0.000931	0.00217	CcSEcCtD
Palonosetron—Shock—Betamethasone—psoriatic arthritis	0.000931	0.00217	CcSEcCtD
Palonosetron—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00093	0.00217	CcSEcCtD
Palonosetron—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000928	0.00216	CcSEcCtD
Palonosetron—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000928	0.00216	CcSEcCtD
Palonosetron—Tachycardia—Dexamethasone—psoriatic arthritis	0.000924	0.00215	CcSEcCtD
Palonosetron—Tachycardia—Betamethasone—psoriatic arthritis	0.000924	0.00215	CcSEcCtD
Palonosetron—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000918	0.00214	CcSEcCtD
Palonosetron—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000916	0.00213	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—psoriatic arthritis	0.000906	0.00211	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—psoriatic arthritis	0.000904	0.00211	CcSEcCtD
Palonosetron—Anorexia—Dexamethasone—psoriatic arthritis	0.000902	0.0021	CcSEcCtD
Palonosetron—Anorexia—Betamethasone—psoriatic arthritis	0.000902	0.0021	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—psoriatic arthritis	0.0009	0.0021	CcSEcCtD
Palonosetron—Fatigue—Triamcinolone—psoriatic arthritis	0.0009	0.00209	CcSEcCtD
Palonosetron—Fatigue—Methylprednisolone—psoriatic arthritis	0.000897	0.00209	CcSEcCtD
Palonosetron—Pain—Triamcinolone—psoriatic arthritis	0.000892	0.00208	CcSEcCtD
Palonosetron—Hypotension—Betamethasone—psoriatic arthritis	0.000885	0.00206	CcSEcCtD
Palonosetron—Hypotension—Dexamethasone—psoriatic arthritis	0.000885	0.00206	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—psoriatic arthritis	0.00088	0.00205	CcSEcCtD
Palonosetron—Immune system disorder—Methotrexate—psoriatic arthritis	0.000876	0.00204	CcSEcCtD
Palonosetron—Convulsion—Prednisone—psoriatic arthritis	0.000875	0.00204	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000874	0.00204	CcSEcCtD
Palonosetron—Hypertension—Prednisone—psoriatic arthritis	0.000872	0.00203	CcSEcCtD
Palonosetron—Chills—Methotrexate—psoriatic arthritis	0.00087	0.00203	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000862	0.00201	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000862	0.00201	CcSEcCtD
Palonosetron—Arthralgia—Prednisone—psoriatic arthritis	0.00086	0.002	CcSEcCtD
Palonosetron—Myalgia—Prednisone—psoriatic arthritis	0.00086	0.002	CcSEcCtD
Palonosetron—Anxiety—Prednisone—psoriatic arthritis	0.000857	0.002	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—psoriatic arthritis	0.000857	0.002	CcSEcCtD
Palonosetron—Insomnia—Dexamethasone—psoriatic arthritis	0.000856	0.00199	CcSEcCtD
Palonosetron—Insomnia—Betamethasone—psoriatic arthritis	0.000856	0.00199	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000854	0.00199	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000851	0.00198	CcSEcCtD
Palonosetron—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00085	0.00198	CcSEcCtD
Palonosetron—Paraesthesia—Betamethasone—psoriatic arthritis	0.00085	0.00198	CcSEcCtD
Palonosetron—Discomfort—Prednisone—psoriatic arthritis	0.00085	0.00198	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—psoriatic arthritis	0.00085	0.00198	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—psoriatic arthritis	0.000844	0.00197	CcSEcCtD
Palonosetron—Erythema—Methotrexate—psoriatic arthritis	0.000844	0.00197	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000836	0.00195	CcSEcCtD
Palonosetron—Dyspepsia—Betamethasone—psoriatic arthritis	0.000833	0.00194	CcSEcCtD
Palonosetron—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000833	0.00194	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—psoriatic arthritis	0.000827	0.00193	CcSEcCtD
Palonosetron—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000825	0.00192	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000824	0.00192	CcSEcCtD
Palonosetron—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000823	0.00192	CcSEcCtD
Palonosetron—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000823	0.00192	CcSEcCtD
Palonosetron—Decreased appetite—Betamethasone—psoriatic arthritis	0.000823	0.00192	CcSEcCtD
Palonosetron—Infection—Prednisone—psoriatic arthritis	0.000819	0.00191	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000817	0.0019	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000817	0.0019	CcSEcCtD
Palonosetron—Fatigue—Dexamethasone—psoriatic arthritis	0.000816	0.0019	CcSEcCtD
Palonosetron—Fatigue—Betamethasone—psoriatic arthritis	0.000816	0.0019	CcSEcCtD
Palonosetron—Shock—Prednisone—psoriatic arthritis	0.000811	0.00189	CcSEcCtD
Palonosetron—Pain—Dexamethasone—psoriatic arthritis	0.00081	0.00189	CcSEcCtD
Palonosetron—Pain—Betamethasone—psoriatic arthritis	0.00081	0.00189	CcSEcCtD
Palonosetron—Nervous system disorder—Prednisone—psoriatic arthritis	0.000808	0.00188	CcSEcCtD
Palonosetron—Tachycardia—Prednisone—psoriatic arthritis	0.000805	0.00187	CcSEcCtD
Palonosetron—Skin disorder—Prednisone—psoriatic arthritis	0.000801	0.00186	CcSEcCtD
Palonosetron—Anorexia—Prednisone—psoriatic arthritis	0.000786	0.00183	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—psoriatic arthritis	0.00078	0.00182	CcSEcCtD
Palonosetron—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000774	0.0018	CcSEcCtD
Palonosetron—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000774	0.0018	CcSEcCtD
Palonosetron—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000769	0.00179	CcSEcCtD
Palonosetron—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000767	0.00179	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000751	0.00175	CcSEcCtD
Palonosetron—Dizziness—Prednisolone—psoriatic arthritis	0.00075	0.00175	CcSEcCtD
Palonosetron—Asthenia—Triamcinolone—psoriatic arthritis	0.000749	0.00174	CcSEcCtD
Palonosetron—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000748	0.00174	CcSEcCtD
Palonosetron—Abdominal pain—Betamethasone—psoriatic arthritis	0.000748	0.00174	CcSEcCtD
Palonosetron—Body temperature increased—Betamethasone—psoriatic arthritis	0.000748	0.00174	CcSEcCtD
Palonosetron—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000748	0.00174	CcSEcCtD
Palonosetron—Asthenia—Methylprednisolone—psoriatic arthritis	0.000747	0.00174	CcSEcCtD
Palonosetron—Insomnia—Prednisone—psoriatic arthritis	0.000746	0.00174	CcSEcCtD
Palonosetron—Paraesthesia—Prednisone—psoriatic arthritis	0.00074	0.00172	CcSEcCtD
Palonosetron—Pruritus—Triamcinolone—psoriatic arthritis	0.000738	0.00172	CcSEcCtD
Palonosetron—Pruritus—Methylprednisolone—psoriatic arthritis	0.000737	0.00172	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—psoriatic arthritis	0.000731	0.0017	CcSEcCtD
Palonosetron—Dyspepsia—Prednisone—psoriatic arthritis	0.000726	0.00169	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—psoriatic arthritis	0.000719	0.00167	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—psoriatic arthritis	0.000719	0.00167	CcSEcCtD
Palonosetron—Decreased appetite—Prednisone—psoriatic arthritis	0.000717	0.00167	CcSEcCtD
Palonosetron—Rash—Prednisolone—psoriatic arthritis	0.000715	0.00167	CcSEcCtD
Palonosetron—Dermatitis—Prednisolone—psoriatic arthritis	0.000715	0.00166	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000714	0.00166	CcSEcCtD
Palonosetron—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000712	0.00166	CcSEcCtD
Palonosetron—Fatigue—Prednisone—psoriatic arthritis	0.000711	0.00166	CcSEcCtD
Palonosetron—Headache—Prednisolone—psoriatic arthritis	0.000711	0.00166	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—psoriatic arthritis	0.00071	0.00165	CcSEcCtD
Palonosetron—Constipation—Prednisone—psoriatic arthritis	0.000705	0.00164	CcSEcCtD
Palonosetron—Dizziness—Triamcinolone—psoriatic arthritis	0.00069	0.00161	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000689	0.0016	CcSEcCtD
Palonosetron—Dizziness—Methylprednisolone—psoriatic arthritis	0.000688	0.0016	CcSEcCtD
Palonosetron—Infection—Methotrexate—psoriatic arthritis	0.000684	0.00159	CcSEcCtD
Palonosetron—Asthenia—Betamethasone—psoriatic arthritis	0.000679	0.00158	CcSEcCtD
Palonosetron—Asthenia—Dexamethasone—psoriatic arthritis	0.000679	0.00158	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000676	0.00157	CcSEcCtD
Palonosetron—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000674	0.00157	CcSEcCtD
Palonosetron—Nausea—Prednisolone—psoriatic arthritis	0.000674	0.00157	CcSEcCtD
Palonosetron—Pruritus—Dexamethasone—psoriatic arthritis	0.00067	0.00156	CcSEcCtD
Palonosetron—Pruritus—Betamethasone—psoriatic arthritis	0.00067	0.00156	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—psoriatic arthritis	0.000669	0.00156	CcSEcCtD
Palonosetron—Vomiting—Triamcinolone—psoriatic arthritis	0.000663	0.00154	CcSEcCtD
Palonosetron—Vomiting—Methylprednisolone—psoriatic arthritis	0.000662	0.00154	CcSEcCtD
Palonosetron—Rash—Triamcinolone—psoriatic arthritis	0.000658	0.00153	CcSEcCtD
Palonosetron—Dermatitis—Triamcinolone—psoriatic arthritis	0.000657	0.00153	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—psoriatic arthritis	0.000657	0.00153	CcSEcCtD
Palonosetron—Rash—Methylprednisolone—psoriatic arthritis	0.000656	0.00153	CcSEcCtD
Palonosetron—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000656	0.00153	CcSEcCtD
Palonosetron—Headache—Triamcinolone—psoriatic arthritis	0.000654	0.00152	CcSEcCtD
Palonosetron—Headache—Methylprednisolone—psoriatic arthritis	0.000652	0.00152	CcSEcCtD
Palonosetron—Body temperature increased—Prednisone—psoriatic arthritis	0.000652	0.00152	CcSEcCtD
Palonosetron—Abdominal pain—Prednisone—psoriatic arthritis	0.000652	0.00152	CcSEcCtD
Palonosetron—Diarrhoea—Betamethasone—psoriatic arthritis	0.000648	0.00151	CcSEcCtD
Palonosetron—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000648	0.00151	CcSEcCtD
Palonosetron—Hypotension—Methotrexate—psoriatic arthritis	0.000644	0.0015	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000628	0.00146	CcSEcCtD
Palonosetron—Dizziness—Betamethasone—psoriatic arthritis	0.000626	0.00146	CcSEcCtD
Palonosetron—Dizziness—Dexamethasone—psoriatic arthritis	0.000626	0.00146	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—psoriatic arthritis	0.000623	0.00145	CcSEcCtD
Palonosetron—Nausea—Triamcinolone—psoriatic arthritis	0.00062	0.00144	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—psoriatic arthritis	0.000619	0.00144	CcSEcCtD
Palonosetron—Nausea—Methylprednisolone—psoriatic arthritis	0.000618	0.00144	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—psoriatic arthritis	0.000614	0.00143	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—psoriatic arthritis	0.000613	0.00143	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisone—psoriatic arthritis	0.000607	0.00141	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—psoriatic arthritis	0.000606	0.00141	CcSEcCtD
Palonosetron—Vomiting—Dexamethasone—psoriatic arthritis	0.000602	0.0014	CcSEcCtD
Palonosetron—Vomiting—Betamethasone—psoriatic arthritis	0.000602	0.0014	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—psoriatic arthritis	0.000599	0.00139	CcSEcCtD
Palonosetron—Rash—Dexamethasone—psoriatic arthritis	0.000597	0.00139	CcSEcCtD
Palonosetron—Rash—Betamethasone—psoriatic arthritis	0.000597	0.00139	CcSEcCtD
Palonosetron—Dermatitis—Dexamethasone—psoriatic arthritis	0.000596	0.00139	CcSEcCtD
Palonosetron—Dermatitis—Betamethasone—psoriatic arthritis	0.000596	0.00139	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000595	0.00139	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—psoriatic arthritis	0.000594	0.00138	CcSEcCtD
Palonosetron—Headache—Dexamethasone—psoriatic arthritis	0.000593	0.00138	CcSEcCtD
Palonosetron—Headache—Betamethasone—psoriatic arthritis	0.000593	0.00138	CcSEcCtD
Palonosetron—Asthenia—Prednisone—psoriatic arthritis	0.000591	0.00138	CcSEcCtD
Palonosetron—Pain—Methotrexate—psoriatic arthritis	0.000589	0.00137	CcSEcCtD
Palonosetron—Pruritus—Prednisone—psoriatic arthritis	0.000583	0.00136	CcSEcCtD
Palonosetron—Diarrhoea—Prednisone—psoriatic arthritis	0.000564	0.00131	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000563	0.00131	CcSEcCtD
Palonosetron—Nausea—Dexamethasone—psoriatic arthritis	0.000562	0.00131	CcSEcCtD
Palonosetron—Nausea—Betamethasone—psoriatic arthritis	0.000562	0.00131	CcSEcCtD
Palonosetron—Dizziness—Prednisone—psoriatic arthritis	0.000545	0.00127	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—psoriatic arthritis	0.000545	0.00127	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—psoriatic arthritis	0.000545	0.00127	CcSEcCtD
Palonosetron—Vomiting—Prednisone—psoriatic arthritis	0.000524	0.00122	CcSEcCtD
Palonosetron—Rash—Prednisone—psoriatic arthritis	0.00052	0.00121	CcSEcCtD
Palonosetron—Dermatitis—Prednisone—psoriatic arthritis	0.000519	0.00121	CcSEcCtD
Palonosetron—Headache—Prednisone—psoriatic arthritis	0.000516	0.0012	CcSEcCtD
Palonosetron—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000508	0.00118	CcSEcCtD
Palonosetron—Asthenia—Methotrexate—psoriatic arthritis	0.000494	0.00115	CcSEcCtD
Palonosetron—Nausea—Prednisone—psoriatic arthritis	0.00049	0.00114	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—psoriatic arthritis	0.000487	0.00114	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—psoriatic arthritis	0.000471	0.0011	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—psoriatic arthritis	0.000456	0.00106	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—psoriatic arthritis	0.000438	0.00102	CcSEcCtD
Palonosetron—Rash—Methotrexate—psoriatic arthritis	0.000434	0.00101	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—psoriatic arthritis	0.000434	0.00101	CcSEcCtD
Palonosetron—Headache—Methotrexate—psoriatic arthritis	0.000432	0.00101	CcSEcCtD
Palonosetron—Nausea—Methotrexate—psoriatic arthritis	0.000409	0.000953	CcSEcCtD
